Diagnostic Approach to Thrombocytosis with Splenomegaly

Primary Myeloproliferative Neoplasms

The American Society of Hematology recommends that essential thrombocythemia (ET) be diagnosed based on sustained platelet count ≥450×10⁹/L, bone marrow biopsy showing megakaryocytic proliferation, exclusion of other myeloid neoplasms, and demonstration of JAK2V617F or other clonal markers (CALR or MPL mutations) 1
Polycythemia vera (PV) presents with elevated hemoglobin/hematocrit, JAK2V617F mutation in >90% of cases, and splenomegaly in 40-50% of patients at diagnosis, according to the European Society for Medical Oncology 2
Primary myelofibrosis (PMF) is associated with JAK2V617F mutation in nearly 50% of cases, characteristic bone marrow fibrosis, atypical megakaryocytes, and progressive splenomegaly, as stated by the International Society for Experimental Hematology 3
Chronic myeloid leukemia (CML) typically presents with marked leukocytosis, splenomegaly in 40-50% of cases, and requires detection of Philadelphia chromosome t(9;22) or BCR-ABL1 transcripts, as recommended by the National Comprehensive Cancer Network 2

The American College of Physicians recommends complete blood count with differential to assess for pancytopenia, leukocytosis, or isolated thrombocytosis 4
Peripheral blood smear examination is mandatory to identify immature myeloid cells, abnormal white cells, red cell fragments, and platelet morphology, according to the College of American Pathologists 4
JAK2V617F mutation testing should be performed immediately when primary thrombocytosis is suspected, as it is present in 86% of ET cases and >90% of PV cases, as stated by the American Society of Hematology 1
Bone marrow biopsy with aspirate is mandatory when thrombocytosis presents with splenomegaly, as this combination strongly suggests MPN, according to the European Society for Medical Oncology 3

Splenomegaly with thrombocytosis is never normal and mandates immediate hematologic workup, as recommended by the International Society for Experimental Hematology 3
Constitutional symptoms suggest underlying malignancy or myelodysplasia, according to the National Comprehensive Cancer Network 4
Abnormal hemoglobin, white blood cell count, or white cell morphology beyond isolated thrombocytosis requires further evaluation, as stated by the American College of Physicians 4
Primary thrombocytosis carries significantly higher thrombotic risk than secondary thrombocytosis, making this distinction critical for mortality reduction, as recommended by the American Society of Hematology 1